References: Managing negative symptoms in psychoses including schizophrenia

  • Correll CU, Rubio JM, Inczedy-Farkas G, Birnbaum ML, Kane JM, Leucht S. Efficacy of 42 pharmacologic cotreatment strategies added to antipsychotic monotherapy in schizophrenia: Systematic overview and quality appraisal of the meta-analytic evidence. JAMA Psychiatry 2017;74(7):675–84. https://www.ncbi.nlm.nih.gov/pubmed/28514486
  • Galletly C, Castle D, Dark F, Humberstone V, Jablensky A, Killackey E, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Aust N Z J Psychiatry 2016;50(5):410–72. https://www.ncbi.nlm.nih.gov/pubmed/27106681
  • Krause M, Zhu Y, Huhn M, Schneider-Thoma J, Bighelli I, Nikolakopoulou A, et al. Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 2018;268(7):625–39. https://www.ncbi.nlm.nih.gov/pubmed/29368205
  • Lutgens D, Gariepy G, Malla A. Psychological and psychosocial interventions for negative symptoms in psychosis: systematic review and meta-analysis. Br J Psychiatry 2017;210(5):324–32. https://www.ncbi.nlm.nih.gov/pubmed/28302699
  • Vancampfort D, Rosenbaum S, Probst M, Soundy A, Mitchell AJ, De Hert M, et al. Promotion of cardiorespiratory fitness in schizophrenia: a clinical overview and meta-analysis. Acta Psychiatr Scand 2015;132(2):131–43. https://www.ncbi.nlm.nih.gov/pubmed/25740655
  • Veerman SRT, Schulte PFJ, de Haan L. Treatment for negative symptoms in schizophrenia: A comprehensive review. Drugs 2017;77(13):1423–59. https://www.ncbi.nlm.nih.gov/pubmed/28776162